The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Len and obinutuzumab in relapsed indolent lymphoma: improving R2?
Although multiple treatment options exist for patients with advanced indolent non-Hodgkin lymphoma (NHL), most are associated with only a short remission or intolerable side effects. Nathan Fowler, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the phase I/II study of lenalidomide and obinutuzumab in relapsed indolent follicular lymphoma (NCT01995669). Overall response rates were high, with many patients achieving prolonged remission, including those who had relapsed after two or more lines of prior therapy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
